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Background: The aim of this study was to investigate the effects of noninvasive   radioelectric 
asymmetric conveyer brain stimulation (REAC-BS) on pain and physical problems, a 
  measurement cluster of the Psychological Stress Measure (PSM) test. When the symptoms of 
pain and physical problems do not respond to various therapeutic approaches such as medication, 
physiotherapy, and psychotherapy, they are often called medically unexplained symptoms. As 
such, these symptoms are reported to be a response to stressful situations or emotional states, 
often unknown to patients themselves. To explore the effectiveness of noninvasive radioelectric 
brain stimulation in the amelioration of symptoms of pain and physical problems, we adminis-
tered a neuropsychophysical optimization protocol using a REAC device.
Methods: The PSM, a self-administered questionnaire, was used to measure psychological stress 
and pain and physical problems in a group of 888 subjects. Data were collected immediately 
prior to and following a 4-week REAC treatment cycle.
Results: There was a significant reduction in scores measuring subjective perceptions of stress 
for subjects treated with one cycle of neuropsychophysical optimization REAC-BS. At the 
end of the study, the number of treated subjects reporting symptoms of stress-related pain and 
physical problems on the PSM test was significantly reduced, whereas there was no difference 
in placebo-treated subjects.
Conclusion: One cycle of neuropsychophysical optimization REAC-BS appears to reduce 
subjective perceptions of stress as measured by the PSM, particularly on the pain and physical 
problems cluster.
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Introduction
Pain and physical problems of various kinds which display a chronic course and do 
not meet diagnostic criteria for specific treatments1 are generally defined as   medically 
unexplained symptoms.2–4 These symptoms may be present in people of all ages and 
social groups,5 and represent a difficult problem for both general practitioners6–8 
and specialists.9 Pain and physical problems and medically unexplained symptoms 
(PPP-MUS) are often considered to be, and treated as, psychiatric disorders.6,10–12 
However, it may be more accurate to consider PPP-MUS as stress-related maladaptive 
illnesses13–15 or psychosomatic disorders, which are classified as “psychological   factors 
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affecting medical condition” in the DSM-IV (Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision).16 The most common PPP-MUS include 
migraine, headaches, neck and low back pain, and joint 
pain. Usually the treatment plan for medically unexplained 
symptoms involves a combination of behavior modification 
and pharmaceutical treatment, as well as good communica-
tion between patient and doctor. The purpose of the current 
work is to determine whether the use of noninvasive radio-
electric asymmetric conveyer brain stimulation (REAC-BS) 
is effective in reducing subjective perceptions of stress as 
measured by the Psychological Stress Measure (PSM) test, 
a validated questionnaire17–19 allowing for the classification 
of a subject’s stress level and stress-related symptoms of pain 
and physical problems.
Materials and methods
Participants
Eight hundred and eighty-eight subjects were included in the 
study from an initial group of 1453 patients (Supplement 1) 
who attended the Rinaldi-Fontani Institute in Florence, Italy. 
These patients presented with different types of stress-related 
PPP-MUS such as migraine, headaches, neck and low back 
pain, joint pain, and functional somatic pain syndrome. In 
all subjects, the pain had been present for several years, and 
patients had found little or no benefit from previous treatments 
including drugs, physiotherapy, or any of several psychothera-
peutic approaches. The subjects included in the study were 
taking pain medication as needed for unbearable pain, but were 
asked not to take specific psychotropic drugs. The study was 
performed in accordance with the Declaration of Helsinki.
Sample size and randomization
This was a naturalistic study, so patients with stress-related 
pain and physical problems came unsolicited to our private 
medical center and were observed in normal clinical practice. 
To obtain a sample of control subjects for comparison with 
the treated patients, two groups were created. Subjects were 
randomly assigned to each group using simple computerized 
randomization by an external operator. Group A subjects 
received active treatment and Group B subjects received 
placebo treatment, ie, inactive REAC, in a specific room, in 
an approximately 3:1 ratio.
Demographic characteristics
Group A included 688 subjects comprising 401 (58.3%) 
females, of average age 42.3 ± 11.3 years, and 287 (41.7%) 
males of average age 41.1 ± 11.4 years. These patients were 
treated with active REAC. Group B included 200 subjects 
comprising 123 (61.5%) females of average age 48.8 ± 19.4 
years, and 77 (38.5%) males of average age 45.8 ± 18.5 
years. These patients were treated with inactive REAC (see 
Table 1).
Psychological and psychiatric assessment
The PSM was developed specifically to detect stress levels 
in a nonclinical population.17–19 The PSM usually consists of 
a 49-item self-report pencil and paper questionnaire. In this 
study, we used an electronic version to collect and process 
the data, and to analyze the results. Patients were asked to 
answer questions about their psychological stress using a 
four-point scale to describe the intensity of their condition 
(very much = 4, much = 3, little = 2, none = 1). The final score 
is expressed in total points. To detect the presence of symp-
toms of pain and physical problems, scores were specifically 
obtained from questions referring to difficulty with digestion, 
stomach pain, feelings of a knot in the stomach (question 12), 
physical aches and pains, including a sore back, headache, 
stiff neck, stomach ache (question 14), diarrhea or intesti-
nal cramping or constipation (question 28). Both groups of 
subjects at time 0 were examined by a psychiatrist to detect 
possible psychiatric disorders that could affect symptoms 
of pain and physical problems. The average total PSM test 
score was 122.53 ± 6.75 for Group A and 122.96 ± 7.041 
for Group B.
REAC technology and therapeutic 
protocol
REAC  is  an  innovative  medical  technology  for 
bioenhancement.20,21 REAC-specific treatments have proven 
efficacious in ameliorating stress-related disorders,22–25 
depression,26 anxiety,25,27 bipolar disorder,28 and other psychi-
atric disorders.29 REAC administration has also been shown 
to be effective in treating neuromotor dysfunction,30 post-
traumatic pain and injury,31,32 and improving functional recov-
ery in arthritic lower limb joints.33,34 REAC utilized a typical 
Table 1 Demographic characteristics
Group A Group B Total
Gender
  Female 401 (58.28%) 123 (62%) 688 (100%)
  Male 287 (41.71%) 77 (39%) 200 (100%)
Age
 n 688 200 888
  Mean 41.8 47.7 43.13
  SD 11.35 19.14 13.71
Abbreviation: SD, standard deviation.
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range of frequencies of 2.4, 5.8, or 10.5 gHz, as selected by 
the operator for each specific protocol. In the brain stimula-
tion protocols used in this study, a frequency of 10.5 gHz was 
used with a specific absorption rate of 7 mW/kg. A sequence 
of seven radiofrequency pulses of 500 milliseconds, termed 
the neuropsychophysical optimization protocol, was applied 
by touching the metallic tip of the REAC probe onto seven 
specific reflex auricular points. This protocol consists of 
18 sessions, usually administered on alternate days. The goal 
of neuropsychophysical optimization is gradual amelioration 
of symptoms of both physical and mental dysfunction. To 
achieve this, the amount of treatment given is in relation to 
symptom severity. The neuropsychophysical optimization 
treatment is painless, simple, rapid, and noninvasive. The 
REAC model used in this study was the Convogliatore di 
Radianza Modulante (ASMED, Italy).
Statistical analysis
Statistical analysis was performed using number needed to 
treat analysis (Table 2). To compare total points before and 
after treatment or placebo, the Wilcoxon signed-rank test was 
used, while the McNemar test was used to test for the pres-
ence of symptoms of pain and physical problems. P , 0.05 
was considered to be statistically significant.
Results
Prior to REAC treatment, 403 (58.58%) patients in Group A 
were positive for stress-related pain and physical problems. 
Table 2 Number needed to treat analysis
Present Absent Total
Given (Group A) 196 496 688
Not given (Group B) 135 65 200
Total 331 557 888
Risk of outcome in treated group
Risk of outcome in control group
Absolute risk reduction
Relative risk
Relative risk reduction
Number needed to treat
0.2848
0.675
0.3901
0.4220
0.5779
2.5633
Table 3 Psychological Stress Measure test results
Subjects Total points PSM test PPP subjects (%) Wilcoxon test
Group A (n = 688), T0 122.53 ± 6.747 403 Asymp sig (two-tailed) 0.000 
Z = -22.735 P , 0.005 Group A, T1   96.01 ± 8.520 196 (48%)
Group B (n = 200), T0 122.96 ± 7.041 159 Asymp sig (two-tailed) 0.361 
Z = -0.914 P . 0.005 Group B, T1 122.11 ± 7.450 135 (85%)
Notes: PSM test results: Total points and Wilcoxon test results obtained in Group A and in Group B, before (T0) and after (T1) NPPO REAC treatment/placebo. Values of 
total points are expressed by mean ± standard deviation. *P , 0.05.
Abbreviations: NPPO, neuropsychophysical optimization; REAC, radioelectric asymmetric conveyer; PSM, Psychological Stress Measure; PPP, pain and physical problems; 
asymp sig, asymptotic significance.
In Group B, pain and physical problems were detected in 159 
(79%) patients. Following REAC treatment, only 196 of 403 
patients (48.63%) in Group A still presented symptoms of 
stress-related pain and physical problems (McNemar Chi-
square test = 170.426, asymptotic significance = 0.000). In 
Group B, pain and physical problems were observed in 135 of 
159 subjects (84.90%). Total point scores decreased signifi-
cantly in Group A subjects following treatment, from 122.3 
to 96.01 (Wilcoxon signed-rank test Z = -22.735, asymptotic 
significance [two-tailed] = 0.000, Table 3). The decrease 
in total point scores from 122.96 to 122.11 in Group B 
was not statistically significant (Wilcoxon signed-rank test 
Z = -0.914, asymptotic significance [two-tailed] = 0.361, 
Table 3). There was no significant effect of age or gender 
upon therapy-induced changes in total points.
Discussion
The REAC reshapes electrical changes due to ion flows,35 
which likely balances the distributions of two main neu-
rotransmitters, ie, excitatory glutamate36 and inhibitory 
gamma aminobutyric acid.37 The neuropsychophysical 
optimization protocol induces a new positive regulation of 
bioelectric activity in the central nervous system, leading 
to normalization of brain function that can be tailored to 
the individual,22–34,38 according to symptoms of pain and 
physical problems. The current study was designed based 
upon the results of a previous study that demonstrated the 
beneficial effects of REAC in stress-related disorders,24 and 
was targeted to assess specific stress-related clusters on the 
PSM test.25 The perception of acute and chronic pain may be 
influenced by stress and the psychological state of sufferers, 
often without awareness.39–50 This unrelieved pain may cause 
the sufferer to use or abuse narcotic drugs, and physicians 
may prescribe painkillers or tranquilizers to reduce the ten-
sion associated with pain.51 Therefore, a targeted therapy that 
improves the neuropsychophysical response to environmental 
stressors could represent a viable alternative to pharmaceuti-
cal treatments. REAC is a noninvasive, drug-free alternative 
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for the treatment of pain, particularly in situations where 
emotional state and stress levels of the individual clearly 
affect overall symptomatology.
Conclusion
This research highlights the efficacy of REAC neuropsy-
chophysical optimization on the pain and physical symptoms 
cluster measurable using the PSM test. The pain and physical 
symptom cluster represents a set of disorders that can severely 
impact quality of life in a large proportion of the population. 
For this reason, it is necessary to find new therapeutic strate-
gies able to treat the various components that underlie these 
symptoms. Of course, because symptoms of pain and physical 
problems are often chronic, it is desirable that efficacious 
treatments also be safe and cost-effective. Further studies are 
needed to verify the stability of symptoms over time when 
using more than one cycle of REAC neuropsychophysical 
optimization, although there may be difficulties in obtaining 
and following a selected group of patients, especially after 
treatment. A longer period of observation and administration 
of additional REAC therapy cycles is necessary to assess the 
stability of their therapeutic effects over time.
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